Dr. Biran Discusses Doublets Versus Triplets in Myeloma

Noa Biran, MD
Published: Friday, Mar 30, 2018



Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses doublets versus triplets in the treatment of patients with multiple myeloma.

Biran says that in the newly diagnosed setting, triplet therapy is better than doublet therapy, both in the transplant-eligible and transplant-ineligible patients. Triplets have shown very rapid and deep responses in these patients, which usually translates into a longer duration of remission, explains Biran.

The SWOG S0777 trial, which evaluated bortezomib (Velcade) with lenalidomide (Revlimid) and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem cell transplant, showed a longer progression-free survival and overall survival in patients who received the triplet. Biran says that these findings show that it is important to keep those who are ineligible for transplant on a triplet regimen.


Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses doublets versus triplets in the treatment of patients with multiple myeloma.

Biran says that in the newly diagnosed setting, triplet therapy is better than doublet therapy, both in the transplant-eligible and transplant-ineligible patients. Triplets have shown very rapid and deep responses in these patients, which usually translates into a longer duration of remission, explains Biran.

The SWOG S0777 trial, which evaluated bortezomib (Velcade) with lenalidomide (Revlimid) and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem cell transplant, showed a longer progression-free survival and overall survival in patients who received the triplet. Biran says that these findings show that it is important to keep those who are ineligible for transplant on a triplet regimen.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x